LBTSF Stock Chart & Stats
$12.02
--
Market closed
$12.02
--
Day’s Range― - ―
52-Week Range$11.27 - $17.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$2.63B
Enterprise Value$2.41K
Total Cash (Recent Filing)$355.41M
Total Debt (Recent Filing)$363.67M
Price to Earnings (P/E)31.5
Beta0.60
Next Earnings
Nov 09, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend Yield1.59%
Share Statistics
EPS (TTM)0.33
Shares Outstanding217,777,330
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)1.85
Price to Sales (P/S)2.49
P/FCF Ratio20.54
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.45
Revenue Forecast (FY)$1.42B
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability ReboundTTM revenue rose 293% versus the prior period and the company returned to solid profitability, with gross margin near 47.5% and net margin near 5.1%. This improves operating scale and supports investment in dermatology growth.
Conservative, Improving Balance SheetLower leverage and growing equity strengthen financial resilience. Debt-to-equity declined from roughly 0.31 to 0.19, giving Almirall more flexibility to fund products, partnerships and commercialization without relying heavily on external capital.
Strong Recent Cash GenerationOperating cash flow and free cash flow both reached about €329M in the latest period, creating internal funding capacity for research, launches and debt management. Strong cash generation can improve resilience if maintained across future reporting periods.
Bears Say
Earnings Durability Remains UnprovenThe sharp rebound is not yet supported by a consistently stable earnings record. Earlier losses and very low profits show that results can fluctuate materially, reducing confidence that current profitability will persist through product or market changes.
Inconsistent Historical Cash FlowRecent cash generation is strong, but the annual history includes negative or breakeven free cash flow. This inconsistency suggests working capital, investment or operating factors can materially affect cash availability and makes long-term conversion less predictable.
Low Returns On Shareholder CapitalReturns remain modest relative to the equity base despite improved earnings. TTM returns of about 4.8%, following near-zero or negative prior results, indicate that capital productivity has not fully normalized and may constrain durable value creation.
Almirall News
LBTSF FAQ
What was Almirall SA’s price range in the past 12 months?
Almirall SA lowest stock price was $11.27 and its highest was $17.20 in the past 12 months.
What is Almirall SA’s market cap?
Almirall SA’s market cap is $2.63B.
When is Almirall SA’s upcoming earnings report date?
Almirall SA’s upcoming earnings report date is Nov 09, 2026 which is in 65 days.
How were Almirall SA’s earnings last quarter?
Almirall SA released its earnings results on Jul 24, 2026. The company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.151 by -$0.021.
Is Almirall SA overvalued?
According to Wall Street analysts Almirall SA’s price is currently Overvalued.
Does Almirall SA pay dividends?
Almirall SA pays a Annually dividend of $0.218 which represents an annual dividend yield of 1.59%. See more information on Almirall SA dividends here
What is Almirall SA’s EPS estimate?
Almirall SA’s EPS estimate is 0.15.
How many shares outstanding does Almirall SA have?
Almirall SA has 217,777,330 shares outstanding.
What happened to Almirall SA’s price movement after its last earnings report?
Almirall SA reported an EPS of $0.13 in its last earnings report, missing expectations of $0.151. Following the earnings report the stock price went up 0.593%.
Which hedge fund is a major shareholder of Almirall SA?
Currently, no hedge funds are holding shares in LBTSF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Almirall Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.23%
12-Months-Change
Fundamentals
Return on Equity
1.59%
Trailing 12-Months
Asset Growth
2.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Almirall SA
Almirall, S.A. is a biopharmaceutical firm dedicated to the discovery, development, production, and commercialization of treatments primarily focused on skin health. Operating globally, with a significant presence in Europe and the United States, its product line targets various dermatological ailments such as actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, and acne, alongside rare skin conditions. Beyond its core dermatology focus, the company also offers solutions for cardiovascular, musculoskeletal, respiratory, and nervous system disorders, as well as products for digestive health, anti-infectives for systemic use, genitourinary conditions and sex hormones, immunostimulants, and systemic hormonal preparations. Its extensive portfolio includes a range of well-known medications, such as Ilumetri, Solaraze, Skilarence, and Klisyri, among others. Almirall fosters strategic partnerships with numerous entities to advance its pipeline, including research institutions like the University of Dundee and commercial partners such as Eli Lilly and Company. Founded in Barcelona, Spain, in 1943, the company adopted its current name, Almirall, S.A., in May 2009, having previously been known as Laboratorios Almirall, S.A.
Technical Analysis
Ownership Overview
―
Insiders
2.84% Mutual Funds
0.15% Other Institutional Investors
94.96% Public Companies and
Individual Investors